Epidémiologie de la coqueluche en Europe en 1995

[Pertussis surveillance in French military forces in 2007]

OBJECTIVES

Pertussis surveillance in the French general population was stopped in 1986. Pertussis was added to the list of illnesses surveyed by the military epidemiological surveillance network because of outbreaks having occurred among French servicepersons and in military high schools. This study had for aim to report the results of the first year of surveillance.

DESIGN

Pertussis declaration criteria were those recommended in 2006 by the French council for public hygiene. The data concerning active military servicepersons was collected by physicians of all military medical units. An anonymous declaration form was used for data collection.

RESULTS

In 2007, 66 cases of pertussis were reported in the military forces, 10 of which were excluded after a negative biological test. The classification of the 56 included cases was: 46% biologically confirmed cases, 20% clinically confirmed cases, 14% suspected cases, and 6% epidemiologically confirmed cases. The incidence density rate was 16.3 cases for 100,000 servicepersons-years. Age under 20 was associated with a 4.6 fold higher risk to develop pertussis.

CONCLUSIONS

The high incidence rate observed in individuals under 20 years of age could reflect a shift of pertussis reservoir to young adults, as observed in industrialized countries after generalization of vaccination programs. However, several years of surveillance will be needed to confirm this hypothesis. Meanwhile, the military epidemiological network could constitute an important surveillance marker of pertussis among adults in France.

Qui faut-il vacciner contre la coqueluche ?

Whooping-cough is one of the rare diseases for which vaccine prevention has been available for many years. However, in spite of good vaccine coverage in the infant, the pertussis infection remains a frequent disease in the teenagers and adults partially immunized. The missing diagnosis of the infection, added to its often clinical banal expression, contributes to support the circulation of Bordetella pertussis and explains the contamination of the young infants in whom the disease remains a true danger as the few declared deaths show it every year. Control of the disease must go through reinforcement of vaccination as a practitioner of booster vaccine in preadolescents, teenagers and adults. Instituted since 1998 in the French vaccine calendar, the 2nd booster in preadolescence between 11-13 years olds or 5th dose of vaccine is not enough carried out and must be encouraged like the installation of another additional vaccine dose for adults and certain professional categories. The protection of infants too young to have received the 3 doses goes through the vaccination of their entourage, family and socio-professional alike. The new recommendations thus preach to begin vaccination in children from the age of 2 months, a reinforcement of the vaccine boosters in preadolescents, in adults likely to become parents and in the medical and paramedical personnel in contact with very young infants.

Environmentally and occupationally acquired diseases in adolescents and adulthood: control of diphtheria, tetanus, pertussis, and poliomyelitis through regular booster vaccinations--a European perspective

Despite the success of childhood vaccination in industrialized countries, diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio) still affect adults and adolescents whose immunity has waned. The resurgence in the 1990s of diphtheria in the area of the former Soviet Union and its subsequent control with immunization campaigns, demonstrates the value of continued adult vaccination. Tetanus cannot be eradicated from the soil reservoir, necessitating routine primary vaccination and regular booster doses to maintain protective immunity. Although Europe has been certified endogenous polio-free since June 2002, polio imported from endemic areas continues to pose a serious threat for vulnerable populations. Booster polio vaccination is required in adolescence and adulthood. Pertussis among adults and adolescents is underestimated, representing a considerable health burden. The consequences can be more serious as this pool of susceptible adolescents and adults is a major source of pertussis transmission to newborns not yet protected by vaccination. The now available acellular pertussis-based combination vaccine covering diphtheria, tetanus, polio, and pertussis, suitable for adults and adolescents, provides the ideal tool for implementing booster immunization programs. Strong recommendations for adolescent and adult boosters are needed to overcome the continued threat of these diseases.

Impfungen im Erwachsenenalter

Despite the success of childhood vaccinations in Europe, many infectious diseases pose a threat to adults, particularly because immunity induced by vaccination is not life long in some cases. This paper presents the rationale for adult boosters for diphtheria, hepatitis B, pertussis, poliomyelitis and tetanus. Moreover indication for adult-vaccinations against measles, mumps, German measles and varicella is discussed, as a significant part of the population in Germany is susceptible or without known immunity/vaccination history. Finally, immunisation of the elderly against infections with influenza-virus and S. pneumoniae will be described.

Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned

The widespread use of whole-cell pertussis vaccines in the second half of the 20th century have reduced the incidence of the disease significantly. However, in some countries, concerns about the reactogenicity and potential neurological damage associated with whole-cell vaccines led to a decrease in vaccine acceptance and an increase in morbidity and mortality of pertussis in several countries. This prompted the development of less reactogenic acellular pertussis vaccines combined with diphtheria and tetanus toxoids, initially in Japan and later in other countries. In Europe, the improved diphtheria, tetanus and acellular pertussis (DTPa) vaccine was first introduced in March 1994. The pertussis component of this DTPa vaccine, developed by Glaxo SmithKline, consists of pertussis toxoid, filamentous haemagglutinin and pertactin. The vaccine is well tolerated, with a lower incidence of adverse reactions than after administration of whole-cell vaccines. The long-lasting efficacy and effectiveness of DTPa vaccines have been extensively documented and these are now the cornerstone of a large range of combined vaccines including DTPa-hepatitis B (HBV), DTPa-inactivated polio (IPV) and DTPa-HBV-IPV. A lyophilised Haemophilus influenzae type b (Hib) vaccine can be reconstituted with all of these liquid combinations. The introduction of well-tolerated and efficacious DTPa vaccines and their more polyvalent combinations has improved the acceptance and simplified the implementation of childhood immunisation. This paper is a review of the technical and scientific difficulties encountered and the lessons learned over the 10-year period that it took to develop and introduce six multivalent vaccines using the Glaxo SmithKline DTPa as a building block.

[Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children]

Severe reactions to whole cell pertussis vaccine are the main reason for the poor adhesion of parents and practitioners to pertussis vaccine booster injections in children, leading to a poor immunization in the population, particularly in young adults. The acellular pertussis vaccine appears to be better tolerated while keeping a good immunogenicity. In a randomized multicentric study on pertussis vaccine booster injection tolerance in 386 15-20 month-old children, we confirmed the better local and general tolerance of the acellular vaccine as compared with the whole cell vaccine. This should help to develop a positive opinion toward pertussis vaccine among parents and practitioners, and to improve the level of active pertussis immunization among children, adolescents, and young adults.

Analysis with a combination of macrorestriction endonucleases reveals a high degree of polymorphism among Bordetella pertussis isolates in eastern France

From 1990 to 1996, routine screening for whooping cough identified 399 patients with a calmodulin-dependent adenylate cyclase-positive test result and yielded 69 Bordetella pertussis isolates. None of the patients were fully vaccinated, and most were less than 6 months old. Analysis of total DNA by pulsed-field gel electrophoresis (PFGE) after XbaI, SpeI, or DraI macrorestriction yielded 19, 15, and 5 different patterns, respectively, whereas ribotyping failed to demonstrate any strain polymorphism. Discrimination among the isolates was improved by combining the PFGE profiles. Some patterns were more frequent, but the corresponding patients were not clearly epidemiologically related. The patterns for two strains obtained during a 3-month period from patients who were neighbors differed by the length of a single DNA fragment. These data strongly suggest that one type of isolate is widely spread throughout the world and is carried by individuals other than patients who develop a true illness.

Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine

BACKGROUND

The high reactogenicity of whole cell pertussis vaccines discourages their use in children. While acellular pertussis vaccines are less reactogenic, their use in diphtheria-tetanus-acellular pertussis (DTPa)-based combinations with Haemophilus influenzae type b conjugate vaccine (Hib) and poliomyelitis vaccines must be evaluated.

OBJECTIVES

To assess the immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (DTPa-IPV) given concurrently with Hib as a mixed vaccine or as separate injections, in comparison with a whole cell pertussis vaccine (DTPw-IPV-Hib).

MATERIALS AND METHODS

This open, randomized, controlled study involved 145 healthy children ages 15 to 24 months. Immunogenicity was evaluated for all vaccine antigens, and reactogenicity was assessed with diary cards.

RESULTS

Serum antibody responses to all vaccine antigens was at least as good as that observed with the pentavalent whole cell vaccine. DTPa-IPV was well-tolerated and less reactogenic than the DTPw-IPV vaccine. Administration of DTPa-IPV and Hib vaccine either separately or mixed did not alter the immunogenicity or reactogenicity profiles.

CONCLUSION

DTPa-IPV vaccine, either separately or mixed with Hib vaccine, was at least as immunogenic and less reactogenic than the DTPw-Hib vaccine. Mixing DTPa-IPV and Hib vaccines did not alter the safety profile when compared with separate injections of both vaccines. A mixed DTPa-IPV-Hib vaccine can be recommended for routine use as a booster dose in primed children.